While ITGA2 has been extensively studied in various solid tumors and other hematologic malignancies, including its involvement in cell adhesion, metastasis, and drug resistance, its contribution to CML pathogenesis and therapy resistance remained unexplored until now. The gene discussed is ITGA2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.